Rebiotix, Inc. Completes Enrollment in Phase II Clinical Trial

In The News:

Rebiotix Inc. has announced that it has completed enrollment in the PUNCH CD Phase 2 clinical trial of RBX2660 (microbiota suspension) for the treatment of recurrent Clostridium difficile-associated diarrhea (CDAD). The study is the first of its kind prospective, multi-center clinical study to evaluate a non-antibiotic, live microbial drug product for the treatment of recurrent CDAD conducted using the same protocol at all sites.

To read the article in its’ entirety please click on the following link:

http://finance.yahoo.com/news/rebiotix-completes-enrollment-phase-2-142400625.html?soc_src=mediacontentstory

 

 

*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.